Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen joins MMRF myeloma consortium

Janssen joins MMRF myeloma consortium

24th June 2013

Janssen has become the latest healthcare company to join the precompetitive consortium of the Multiple Myeloma Research Foundation (MMRF).

As part of this consortium, Janssen will help to discover and accelerate new approaches to treating multiple myeloma through the MMRF's Personalised Medicine Initiative (PMI), providing both scientific and financial support.

The key element of the PMI is the landmark CoMMpass trial, which aims to collect cutting-edge clinical information and molecular profiles from 1,000 newly diagnosed patients over a minimum of five years.

Having opened for enrolment in July 2011, the study will help to more completely characterise the genetic subtypes of multiple myeloma based on responsiveness to specific treatments, aiding the future development of personalised therapy regimens.

Walter Capone, chief operating officer of the MMRF, said: "Our partnership with the oncology industry's leaders will help to drive scientific and clinical innovation through new models of collaboration."

Earlier this month, Janssen entered into a new collaboration with KU Leuven, University Hospitals Leuven and Vlaams Instituut voor Biotechnologie to develop new neurodegenerative disease therapies.ADNFCR-8000103-ID-801602818-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.